<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &#x00026; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24520438</article-id><article-id pub-id-type="pmc">3850298</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-6-189</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject><subj-group><subject>Gynecology and Female Infertility</subject><subject>Pharmacognosy</subject></subj-group></subj-group></article-categories><title-group><article-title>Fertility Outcome after Treatment of Unruptured Ectopic Pregnancy
with Two Different Methotrexate Protocols</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tabatabaii Bafghi</surname><given-names>Afsar</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Zaretezerjani</surname><given-names>Fatemah</given-names></name><degrees>M.D.</degrees><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Sekhavat</surname><given-names>Leila</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Dehghani Firouzabadi</surname><given-names>Raziah</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Ramazankhani</surname><given-names>Zeynab</given-names></name><degrees>M.D.</degrees></contrib><aff id="A">Department of Obstetrics and Gynecology, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences
and Health Services, Yazd, Iran</aff></contrib-group><author-notes><corresp id="cor1">
* Corresponding Address:
<addr-line>P.O. Box: 374</addr-line><addr-line>Department of Obstetrics
and Gynecology</addr-line><addr-line>Shahid Sadoughi Hospital</addr-line><institution>Shahid Sedughi University
of Medical Sciences and Health Services</institution><addr-line>Yazd</addr-line><country>Iran</country>
Email: <email>zaretez@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2012</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2012</year></pub-date><volume>6</volume><issue>3</issue><fpage>189</fpage><lpage>194</lpage><history><date date-type="received"><day>19</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2012</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>The purpose of this study was to compare the success rates of 70 patients from the
same database, each with an ectopic pregnancy (EP) that was treated with either the single- or
multi-dose methotrexate (MTX) protocols for unruptured EPs.</p></sec><sec><title>Materials and Methods:</title><p>This study was a blinded, randomized clinical trial. Treatment protocols
were either single- (50 mg/m<sup>2</sup>) dose MTX or multi-dose (1 mg/kg MTX + 0.1 mg/kg folinic acid).
There were 35 cases in each group. The outcome was measured by adverse events, resolution of
pregnancy without surgical treatment, success rate of MTX treatment, and fertility outcome in each
group.</p></sec><sec><title>Results:</title><p>With the single-dose protocol, response to treatment was considered successful in 29
(82.9%) patients; in the multi-dose protocol 31 (88.6%) responded to treatment. The difference
between success rates in the groups was not statistically significant (p=0.587). In the singledose
group, 2 (5.7%) patients and in the multi-dose group, 6 (17.2%) patients had complications
(p=0.28). Of the 14 patients in the single-dose group. Clinical pregnancy occurred in 9 (75%)
whereas clinical pregnancy occurred in 3 (25%) patients from the multi-dose group. Infertility
was seen in 4 (33.3%) patients in the single-dose group and in 8 (66.7%) in the multi-dose
group.</p></sec><sec><title>Conclusion:</title><p>We believe that the single-dose MTX protocol could be as successful as multi-dose
MTX for the treatment of EP. It is effective, cost-effective, and associated with better fertility
outcomes than the multi-dose MTX protocol (Registration Number: IRCT201112178435N1).</p></sec></abstract><kwd-group><kwd>Ectopic Pregnancy</kwd><kwd>Methotrexate</kwd><kwd>Pragnacy Outcome</kwd><kwd>Complication</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Tabatabaii Bafghi A, Zaretezerjani F, Sekhavat L, Dehghani Firouzabadi R, Ramazankhani Z. Fertility outcome after treatment
of unruptured ectopic pregnancy with two different methotrexate protocols. Int J Fertil Steril. 2012; 6(3): 189-194.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>In modern obstetrics, ectopic pregnancy (EP) is
a life- and fertility-threatening condition, and it remains
one of the leading causes of maternal morbidity
and mortality. In industrialized countries,
EP is a well-documented obstetric disorder, however
in developing countries its data are relatively
rare and unreliable (<xref rid="B1" ref-type="bibr">1</xref> ).</p><p>Approximately 90% of EPs are located in the one or
both fallopian tubes, and 80% of those are located in
the ampullary segment of the tubes (<xref rid="B2" ref-type="bibr">2</xref> ). EP accounts
for 73% of first trimester pregnancy mortalities (<xref rid="B3" ref-type="bibr">3</xref> ).</p><p>However, improved modalities of early diagnosis
and treatment have decreased both pregnancyrelated
mortality and morbidity (<xref rid="B4" ref-type="bibr">4</xref> ). Currently, the
increased availability of &#x003b2;-human chorionic gonadotropin
(&#x003b2;-hCG) and transvaginal ultrasound
have increased the likelihood of early detection
and intervention prior to tubal rupture. The use
of methotrexate (MTX) as a treatment for EP has
been first reported by Tanaka et al. (<xref rid="B5" ref-type="bibr">5</xref> ).</p><p>Management of an unruptured EP and a single
dose MTX regime for treatment was initially described
by Stovall et al. (<xref rid="B6" ref-type="bibr">6</xref> ). It has become a great
alternative to laparoscopic surgical intervention in non-disturbed tubal EPs (<xref rid="B7" ref-type="bibr">7</xref> ). MTX belongs to
a class of drugs known as folic acid antagonists,
which are commonly used in medical treatment of
EP. The half-life of MTX is 8-15 hours for doses
over 30 mg/m<sup>2</sup> (<xref rid="B8" ref-type="bibr">8</xref> ). Rapidly dividing cells, such
as trophoblasts, are the most sensitive to MTX
therapy (<xref rid="B9" ref-type="bibr">9</xref> , <xref rid="B10" ref-type="bibr">10</xref> ). Some studies have reported results
comparable to surgery for the treatment of EPs
(<xref rid="B11" ref-type="bibr">11</xref> ). EP treatment with MTX requires a followup.
The success rates of medical treatment of EP
vary from 75% to 95% (<xref rid="B12" ref-type="bibr">12</xref> ). MTX treatment is
preferred for patients with hemodynamic stability,
no fetal cardiac activity at ultrasonography, pretreatment
&#x003b2;-hCG levels less than 10000 IU/L, and
normal hepatic and renal function tests (<xref rid="B13" ref-type="bibr">13</xref> ).</p><p>Medical management of an unruptured EP with
MTX is common and cost effective (<xref rid="B12" ref-type="bibr">12</xref> ). Systemic
MTX has been administered in single- and multiple-
dose protocols, the previous regimen has been
supported by some to improve patient compliance
and reduce the side effects of treatment (<xref rid="B14" ref-type="bibr">14</xref> ).</p><p>On the other hand, a meta-analysis demonstrated
that multi-dose MTX was significantly better than
single-dose MTX (<xref rid="B12" ref-type="bibr">12</xref> ). A non-randomized prospective
study that compared the two medical regimens
conducted by Lipscomb et al. (<xref rid="B15" ref-type="bibr">15</xref> ) showed
no significant difference in failure rate between
single- and multiple-dose protocols.</p><p>The single-dose regimen involves a one time administration
of 50 mg/m<sup>2</sup> MTX. &#x003b2;-hCG values are
then observed on days 4 and 7. If a 15% hCG level
reduction does not occur, a second dose is required
(<xref rid="B6" ref-type="bibr">6</xref> , <xref rid="B16" ref-type="bibr">16</xref> ). This protocol has been developed in an effort
to reduce the incidence of side effects from multiple
doses of MTX, eliminate the need for leucovorin rescue,
and to increase the convenience of administration.
Success rates for each protocol are based on extended
case studies and vary among different studies,
although a few studies have demonstrated comparable
success rates between the two protocols (<xref rid="B15" ref-type="bibr">15</xref> , <xref rid="B17" ref-type="bibr">17</xref> ).</p><p>The goal of this study was to compare the safety
and success rates of single- and multiple-dose MTX
protocols for the treatment of unruptured tubal EP.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>This was a blinded, randomized clinical trial
study performed from 2009-2010 at Shahid
Sadoughi Hospital, Yazd, Iran. The hospital is a
tertiary regional and teaching hospital. The study
was approved by the Committee for Ethics of Shahid
Sadughi University of Medical Sciences. Institutional
Review Board approval was obtained before
commencing the trial as well. All patients and
their husbands signed written informed consent.</p><sec><title>Patient selection</title><p>
Diagnosis was confirmed by laparoscopic surgery
and vaginal sonography. Inclusion criteria for
patient selection for medical treatment were: absence
of bleeding in evidences of laparoscopic surgery
and vaginal sonography, stable hemodynamic
state, tubal mass (estimated as the biggest diameter
of entire tube with gestation seen by vaginal ultrasonography)
&#x02264;4 cm in diameter, absence of fetal
heart beat, &#x003b2;-hCG less than 15000 mIU/mL, and
leaning of patient to the next pregnancies.</p><p>To diagnose EP, patients with positive &#x003b2;-hCG
were followed until an intrauterine pregnancy was
documented. Serum &#x003b2;-hCG concentrations were
measured at the Central Chemical Laboratory of
our hospital. The assay was calibrated using the
World Health Organization (WHO) Third International
Standard (code 75/537) (formerly designated
the WHO First International Reference Preparation).
In patients who had records of &#x003b2;-hCG levels
from other laboratories, we measured their levels
again at our hospital at the beginning of treatment,
and these new records were used for analyses.</p><p>An EP was diagnosed if &#x003b2;-hCG levels were &#x02265;1800
mlU/mL and no viable intrauterine pregnancy was
evident. Suspected EP with &#x003b2;-hCG levels &#x0003c;1800
mIU/mL was followed according to the algorithm
of Stovall and Ling (<xref rid="B14" ref-type="bibr">14</xref> ):</p><list list-type="roman-lower"><list-item><p>a &#x02265;50% increase in &#x003b2;-hCG over 48 hours was
considered a normal intrauterine pregnancy.</p></list-item><list-item><p>Declining &#x003b2;-hCG levels over 48 hours were
followed by additional serial &#x003b2;-hCG samples and
clinical status.</p><p>These cases were considered spontaneous abortions
or EP in resorption. Cases judged by the
treating clinician to be an EP in resorption were
not suitable to enter the study.</p></list-item><list-item><p>Plateauing levels or a &#x0003c;50% increase in &#x003b2;-hCG
over 48 hours were diagnosed as EPs. These criteria Plateauing levels or a &#x0003c;50% increase in &#x003b2;-hCG
over 48 hours were diagnosed as EPs. These criteria</p></list-item></list></sec><sec><title>Randomization</title><p>
In this study, we used a computer generated block
randomization method with sealed envelopes (<xref rid="B18" ref-type="bibr">18</xref> ).
Therefore, according to a computerized random
table the patients were assigned to either singleor
multiple-doses of MTX (Methotrexate, Ebewe,
Unterach or Vnterach, Austria) by intramuscular
injection. The numbers were kept in sealed envelopes
and only opened once the decision to progress
to treatment was made. The envelopes were stored
and opened by an independent coordinator in an
office away from the treatment center.</p></sec><sec><title>Treatment protocol</title><sec><title>Single-dose regimen</title><p>In the single dose regimen, 50 mg/m<sup>2</sup> intramuscular
MTX (Ebetrex 50 mg/ml, Ebewe Pharma
Ges.m.b.h Ntg.KG, A-4866 Unterach or Vnterach,
Austria) was administered on day 1 and &#x003b2;-hCG levels
were measured on days 4 and 7. If the hCG level
did not decrease by 15% between days 4 and 7, a
second dose of MTX was injected on day 7. If a
more than 15% decline was achieved between days
4 and 7, the &#x003b2;-hCG level was measured weekly until
a normal level of 10 mIU/mL was obtained.</p></sec><sec><title>Multi-dose regimen</title><p>
Intramuscular MTX (1 mg/kg/day) was administered
on days 1, 3, 5, and 7 and citrovorum factor (0.1 mg/
kg/day) was administered on days 2, 4, 6, and 8 or after
a decline in the &#x003b2;-hCG level on two consecutive days.</p></sec><sec><title>Outcome measures</title><p>
The main outcome was a comparison of the success
rates between single- and multiple-dose protocols.
Success rate was defined as the percent of
patients with a positive response to therapy. In the
single-dose group, positive response was defined as
confirmation of a 15% drop in serum &#x003b2;-hCG levels
after one week of treatment, followed by serum
hCG less than 15 mIU/mL after six weeks of treatment.
In the multiple-dose treatment group, a positive
response was defined as a decrease in hCG levels
of 15% in 48 hours or after four doses of MTX
were given, or serum hCG less than 15 mIU/mL
after six weeks of treatment (<xref rid="B19" ref-type="bibr">19</xref> , <xref rid="B20" ref-type="bibr">20</xref> ). At 12 months
after treatment the patients had follow up visits. We
telephoned the study participants and questioned
them about the outcome of the next pregnancy and
of the use of pregnancy prevention methods during
the two months following medical treatment.</p></sec><sec><title>Statistical analysis</title><p>
Our statistical power calculation showed that 35
patients were needed in each group for 80% power,
with side effects of MTX of 20% and an alpha
of 5%. Results are presented as mean &#x000b1; SD or percentile.
Statistical analysis was conducted using a
Mann-Whitney test, student&#x02019;s t test for quantified
data, and Chi-square for qualitative data. P&#x0003c;0.05
was considered significant. Data analysis was carried
out using the Statistical Package for Social
Sciences version 19.0 (SPSS, Chicago, IL).</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>No statistically significant differences were found
between single- and multiple-dose MTX groups in
terms of clinical and laboratory characteristics (<xref ref-type="table" rid="T1">Table
1</xref>). Both single- and multiple-dose MTX groups
did not have a statistically significant difference
with respect to their initial serum &#x003b2;-hCG concentrations
(<xref ref-type="table" rid="T1">Table 1</xref>), nor was there a significant difference
with respect to their serum &#x003b2;-hCG levels seven
days after treatment (680 vs. 1100, p=0.326).</p><p>Of the 35 patients on the single-dose protocol,
treatment was considered successful in 29 (82.9%).
Of the patients on the multiple-dose protocol, 31
(88.6%) responded positively to treatment. The
difference between success rates in the two groups
was not statistically significant (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>Complications were seen in 8 patients, 2 in the
single-dose (5.7%) and 6 in the multiple-dose group
(17.2%; p=0.28). The most frequent complaint was
hair loss which was observed in 2 (5.7%) patients
from the single-dose and 5 (14.3%) from the multidose
group. Stomatitis was seen in 1 (2.9%) patient
in the multi-dose group. Of the 70 total patients
from both groups, 45 had contraception and 25 became
pregnant. A total of 9 patients out of 14 in the
single-dose group and 3 in the multi-dose regimen
became pregnant. Infertility was seen in 4 (33.3%)
single-dose patients and 8 (66.7%) multi-dose patients.
There was one abortion in the single-dose
group (4%; <xref ref-type="table" rid="T3">Table 3</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Comparison of clinical and laboratory characteristics
between single-dose and multi-dose treatments with
methotrexate (MTX)</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Single-dose (n=35)</th><th rowspan="1" colspan="1">Multi-dose (n=35)</th><th rowspan="1" colspan="1">P value</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age (Years)</bold></td><td rowspan="1" colspan="1">28.2 &#x000b1; 4.1</td><td rowspan="1" colspan="1">30 &#x000b1; 5.8</td><td rowspan="1" colspan="1">0.140<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gestational age (Weeks)</bold></td><td rowspan="1" colspan="1">7.3 &#x000b1; 1.7</td><td rowspan="1" colspan="1">7.2 &#x000b1; 2.06 </td><td rowspan="1" colspan="1">0.849<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold> &#x003b2;-hCG at initiation of treatment (mIU/mL)</bold></td><td rowspan="1" colspan="1">910</td><td rowspan="1" colspan="1">1640</td><td rowspan="1" colspan="1">0.288<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Endometrial thickness (mm)</bold></td><td rowspan="1" colspan="1">7.3 &#x000b1; 5.5</td><td rowspan="1" colspan="1">8.7 &#x000b1; 4.1</td><td rowspan="1" colspan="1">0.253<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Size of mass on sonography (cm)</bold></td><td rowspan="1" colspan="1">3.2 &#x000b1; 2.8 </td><td rowspan="1" colspan="1">2.9 &#x000b1; 1.9</td><td rowspan="1" colspan="1">0.575<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Size of mass on laparoscopic surgery (cm)</bold></td><td rowspan="1" colspan="1">3.2 &#x000b1; 2.8</td><td rowspan="1" colspan="1">2.9 &#x000b1; 1.9</td><td rowspan="1" colspan="1">0.575<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Time that &#x003b2;-hCG level reached &#x0003c;10 (mIU/mL) (Weeks)</bold></td><td rowspan="1" colspan="1">3.3 &#x000b1; 1.4</td><td rowspan="1" colspan="1">3.7 &#x000b1; 1.3</td><td rowspan="1" colspan="1">0.195<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Symptoms on admission:</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.174<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold> Vaginal bleeding</bold></td><td rowspan="1" colspan="1">16 (45.7%)</td><td rowspan="1" colspan="1">19 (54.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Abdominal pain</bold></td><td rowspan="1" colspan="1">6 (17.1%)</td><td rowspan="1" colspan="1">6 (17.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Amenorrhea</bold></td><td rowspan="1" colspan="1">1 (2.9%)</td><td rowspan="1" colspan="1">2 (5.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold> Vaginal bleeding + abdominal pain</bold></td><td rowspan="1" colspan="1"> 12 (34.3%)</td><td rowspan="1" colspan="1">8 (22.8%)</td><td rowspan="1" colspan="1"/></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean &#x000b1; standard deviation, or number
of patients with percentages in parentheses.
a; Student&#x02019;s t test, b; Chi-square test and c; Mann-Whitney test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Treatment success as defined</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Single-dose (n=35)</th><th rowspan="1" colspan="1">Multi-dose (n=35)</th><th rowspan="1" colspan="1">P value</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Success rate </bold></td><td rowspan="1" colspan="1">29 (82.9%)</td><td rowspan="1" colspan="1">31 (88.6%)</td><td rowspan="1" colspan="1">0.587<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Subjects with
ruptured EP and
selected for surgery</bold></td><td rowspan="1" colspan="1">3 (8.6%)</td><td rowspan="1" colspan="1">3 (8.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Subjects selected
for repeating the
treatment</bold></td><td rowspan="1" colspan="1">3 (8.6%)</td><td rowspan="1" colspan="1">1 (2.9%)</td><td rowspan="1" colspan="1"/></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>a; Chi-square test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Fertility outcome after treatment for ectopic pregnancy</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Single-dose (n=14)</th><th rowspan="1" colspan="1">Multi-dose (n=11)</th><th rowspan="1" colspan="1">P value</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Clinical pregnancy</bold></td><td rowspan="1" colspan="1">9 (75%)</td><td rowspan="1" colspan="1">3 (25%)</td><td rowspan="1" colspan="1">0.137<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Infertility</bold></td><td rowspan="1" colspan="1">4 (33.3%)</td><td rowspan="1" colspan="1">8 (66.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Abortion</bold></td><td rowspan="1" colspan="1">1 (4%)</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1"/></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>a; Chi-square test.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>MTX is a folinic acid antagonist that blocks DNA,
and to some extent RNA, synthesis, and cell division.
As a result, tissues that have a rapid cell turn
over, such as trophoblasts, are most sensitive to
treatment with MTX (<xref rid="B21" ref-type="bibr">21</xref> ). Although MTX is used
in as treatment for EP, its success rate varies in different
studies and can increase up to 94% (<xref rid="B12" ref-type="bibr">12</xref> ). van
Mello et al. (<xref rid="B22" ref-type="bibr">22</xref> ) have shown that MTX multi-dose
intramuscular regimens can be recommended for
women with unruptured tubal EP, no signs of active
bleeding who present with serum &#x003b2;-hCG concentrations
&#x0003c;3000 IU/L. However this regimen is more
costly than laparoscopic surgery.</p><p>In our study, the success rates of treatment with
single-dose MTX was 82.9% and with multi-dose
treatment it was 88.6%. Alleyassin et al. (<xref rid="B23" ref-type="bibr">23</xref> ) have
shown an 88.9% success rate for single-dose and
92.6% success rate for multi-dose treatment. In a
meta-analysis published by Barnhart et al. (<xref rid="B12" ref-type="bibr">12</xref> ), the
success rates for single-dose was 88.1% and 92.7%
for multi-dose. These researchers noted that none
of the trials reviewed were controlled or blinded.
In their opinion, a randomized blinded clinical trial
would be the most efficient method to reduce potential
confounders and bias in comparing the success
rate of the two methods.</p><p>In one study, multi-dose treatment was reported to be
more successful (93% vs. 88%); on the other hand, it
was noted that in a single-dose treatment there was no
need for folate, a lesser need for monitoring, less side
effects (28% vs. 48%), MTX treatment was as effective
as laparoscopy, and it was inexpensive (<xref rid="B19" ref-type="bibr">19</xref> ). Soliman et
al. (<xref rid="B24" ref-type="bibr">24</xref> ) have reported their success rate as 86.7% and
Srivichai et al. (<xref rid="B25" ref-type="bibr">25</xref> ) reported a success rate of 90% for
single-dose MTX treatment. They pointed out that in
patients with high &#x003b2;-hCG levels prior to treatment and
large adnexal mass images on sonography, either multidose
MTX or surgical treatment would be preferred.
Rozenberg et al. (<xref rid="B26" ref-type="bibr">26</xref> ) found that the success rate of
medical treatment was 77.1% and the efficacy of MTX
was not improved by the addition of mifepristone.</p><p>Potter et al. (<xref rid="B27" ref-type="bibr">27</xref> ) had an 85% overall success rate
with single-dose MTX treatment. A higher &#x003b2;-hCG
level was associated with a lower success rate of treatment;
in addition, they observed that visualization of
a yolk sac was a risk factor for treatment failure.</p><p>There is evidence that the multi-dose protocol
is more successful than the single-dose protocol
(<xref rid="B12" ref-type="bibr">12</xref> ), even though it requires more office visits
and blood draws. Although the single-dose protocol is simpler, approximately 20% of patients
who are treated with this method require at least
one additional dose of MTX (<xref rid="B12" ref-type="bibr">12</xref> , <xref rid="B28" ref-type="bibr">28</xref> -<xref rid="B30" ref-type="bibr">30</xref> ). Other
studies have also demonstrated that MTX is a
safe, effective medical treatment for unruptured
EP, and that life threatening complications have
been rare (<xref rid="B31" ref-type="bibr">31</xref> , <xref rid="B32" ref-type="bibr">32</xref> ).</p><p>In our study the two groups were similar according
to both clinical and laboratory characteristics.
The incidence of infertility was higher
in the multiple-dose treatment group. It does not
seem to play an important role in the dissimilarity
of the two groups, because there was no
statistically significant difference in mean gestational
age and mean serum &#x003b2;-hCG at the time
of diagnosis (<xref rid="B33" ref-type="bibr">33</xref> ). Bouyer et al. (<xref rid="B34" ref-type="bibr">34</xref> ) have noted
that the subsequent intrauterine pregnancy rate
in the presence of such factors is higher with
MTX than with surgical treatment.</p><p>Hajenius et al. have demonstrated that in tubal
EP, systemic treatment with MTX is as effective
as surgery, and the success rate is similar for tubal
patency and a future intrauterine pregnancy (<xref rid="B35" ref-type="bibr">35</xref> ).
This conflicts with other studies that have shown
such factors (history of infertility and contralateral
tubal disease) to be associated with a lower subsequent
intrauterine pregnancy rate and higher rate
of recurrent EP with conservative surgery (<xref rid="B36" ref-type="bibr">36</xref> ).
According to other studies, there is no statistically
significant difference between single- and multiple-
dose treatment regimens in relation to symptoms
which were chief complains of patients (<xref rid="B37" ref-type="bibr">37</xref> -
<xref rid="B40" ref-type="bibr">40</xref> ). In our study, the success rate was 82.9% in the
single-dose and 88.6% in the multi-dose treatment
group. We failed to find a statistically significant
difference between the two groups.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The results of this study have shown that a single-
dose MTX protocol can be as successful as
a multi-dose protocol for the treatment of EP. A
single-dose regimen is also effective, cost-effective,
and associated with a better fertility outcome
than multi-dose treatment. We believe that further
research is warranted before a final decision is
reached regarding which medical treatment is best
as the initial step in treatment for an unruptured
ectopic tubal pregnancy.</p></sec></body><back><ack><p>We would like to thank our Obstetrics and
Gynecology Ward colleagues who helped us
in many ways. We particularly express our appreciation
to Ms. Zakizadeh, the Head Nurse of
the Obstetrics and Gynecology Ward for her assistance.
No company or organization supported
budget for this study. There is no conflict of interest
in this article.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyaux</surname><given-names>N</given-names></name><name><surname>Leke</surname><given-names>R</given-names></name><name><surname>Keita</surname><given-names>N</given-names></name><name><surname>Thonneau</surname><given-names>P</given-names></name></person-group><article-title>Ectopic pregnancy in African developing countries</article-title><source>Acta Obstet Gynecol Scand</source><year>2003</year><volume>82</volume><issue>4</issue><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">12716313</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>JA</given-names></name><name><surname>Clark</surname><given-names>JF</given-names></name></person-group><article-title>Correlation of symptoms with age and location of gestation in tubal pregnancy</article-title><source>J Natl Med Assoc</source><year>1968</year><volume>60</volume><issue>3</issue><fpage>221</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">5661191</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condous</surname><given-names>G</given-names></name></person-group><article-title>Ectopic pregnancy--risk factors and diagnosis</article-title><source>Aust Fam Physician</source><year>2006</year><volume>35</volume><issue>11</issue><fpage>854</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">17099802</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukul</surname><given-names>LV</given-names></name><name><surname>Teal</surname><given-names>SB</given-names></name></person-group><article-title>Current management of ectopic pregnancy</article-title><source>Obstet Gynecol Clin North Am</source><year>2007</year><volume>34</volume><issue>3</issue><fpage>403</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">17921007</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Kutsuzawa</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>S</given-names></name><name><surname>Ichinoe</surname><given-names>K</given-names></name></person-group><article-title>Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case</article-title><source>Fertil Steril</source><year>1982</year><volume>37</volume><issue>6</issue><fpage>851</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">7084507</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stovall</surname><given-names>TG</given-names></name><name><surname>Ling</surname><given-names>FW</given-names></name><name><surname>Gray</surname><given-names>LA</given-names></name></person-group><article-title>Single-dose methotrexate for treatment of ectopic pregnancy</article-title><source>Obstet Gynecol</source><year>1991</year><volume>77</volume><issue>5</issue><fpage>754</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">2014091</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajenius</surname><given-names>PJ</given-names></name><name><surname>Mol</surname><given-names>BW</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Ankum</surname><given-names>WM</given-names></name><name><surname>Van Der Veen</surname><given-names>F</given-names></name></person-group><article-title>Interventions for tubal ectopic pregnancy</article-title><source>Cochrane Database Syst Rev</source><year>2000</year><issue>2</issue><fpage>CD000324</fpage><lpage>CD000324</lpage><pub-id pub-id-type="pmid">10796710</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><article-title>Methotrexate sodium for injection (Package insert)</article-title><comment>Availaible from :<uri xlink:href="http://www.fda.gov/medwatch/SAFETY/2004/jan_PI/Methotrexate_PI.pdf.">http://www.fda.gov/medwatch/
SAFETY/2004/jan_PI/Methotrexate_PI. pdf.</uri>(10 Jan 2004)</comment></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farber</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>LK</given-names></name></person-group><article-title>Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4- aminopteroyl-glutamic acid</article-title><source>N Engl J Med</source><year>1948</year><volume>238</volume><issue>23</issue><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">18860765</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname><given-names>NI</given-names></name><name><surname>Rall</surname><given-names>D</given-names></name><name><surname>Mead</surname><given-names>JA</given-names></name><name><surname>Freireich</surname><given-names>EJ</given-names></name><name><surname>Vanscott</surname><given-names>E</given-names></name><name><surname>Hertzr</surname><given-names>R</given-names></name><etal/></person-group><article-title>Folic acid antagonist.effects on the cell and the patient.Combined clinical staff conference at National Institutes Health</article-title><source>Ann Intern Med</source><year>1963</year><volume>59</volume><fpage>931</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">14082744</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajenius</surname><given-names>PJ</given-names></name><name><surname>Engelsbel</surname><given-names>S</given-names></name><name><surname>Mol</surname><given-names>BW</given-names></name><name><surname>Van der Veen</surname><given-names>F</given-names></name><name><surname>Ankum</surname><given-names>WM</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy</article-title><source>Lancet</source><year>1997</year><volume>350</volume><issue>9080</issue><fpage>774</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">9297998</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnhart</surname><given-names>KT</given-names></name><name><surname>Gosman</surname><given-names>G</given-names></name><name><surname>Ashby</surname><given-names>R</given-names></name><name><surname>Sammel</surname><given-names>M</given-names></name></person-group><article-title>The medical management of ectopic pregnancy: a metaanalysis comparing &#x02018;&#x02018;single dose&#x02019;&#x02019; and &#x02018;&#x02018;multidose&#x02019;&#x02019; regimens</article-title><source>Obstet Gynecol</source><year>2003</year><volume>101</volume><issue>4</issue><fpage>778</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">12681886</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukul</surname><given-names>LV</given-names></name><name><surname>Teal</surname><given-names>SB</given-names></name></person-group><article-title>Current management of ectopic pregnancy</article-title><source>Obstet Gynecol Clin North Am</source><year>2007</year><volume>34</volume><issue>3</issue><fpage>403</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">17921007</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stovall</surname><given-names>TG</given-names></name><name><surname>Ling</surname><given-names>FW</given-names></name></person-group><article-title>Ectopic pregnancy.Diagnostic and therapeutic algorithms minimizing surgical intervention</article-title><source>J Reprod Med</source><year>1993</year><volume>38</volume><issue>10</issue><fpage>807</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">8263872</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>GH</given-names></name><name><surname>Givens</surname><given-names>VM</given-names></name><name><surname>Meyer</surname><given-names>NL</given-names></name><name><surname>Bran</surname><given-names>D</given-names></name></person-group><article-title>Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2005</year><volume>192</volume><issue>6</issue><fpage>1844</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">15970826</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><collab>ACOG practice bulletin</collab><article-title>Medical management of tubal pregnancy.Number 3, December 1998.Clinical management guidelines for obstetrician-gynecologists.American College of Obstetricians and Gynecologists</article-title><source>Int J Gynaecol Obstet</source><year>1999</year><volume>65</volume><issue>1</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">10390113</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klauser</surname><given-names>C</given-names></name><name><surname>May</surname><given-names>W</given-names></name><name><surname>Johnson</surname><given-names>V</given-names></name><name><surname>Cowan</surname><given-names>B</given-names></name><name><surname>Bryan</surname><given-names>D</given-names></name><name><surname>Hines</surname><given-names>R</given-names></name><etal/></person-group><article-title>Methotrexate for ectopic pregnancy:
a randomized &#x0201c;single dose&#x0201d; compared with &#x0201c;multidose&#x0201d; trial</article-title><source>Obstet Gynecol</source><year>2005</year><volume>105</volume><issue>4</issue><fpage>64</fpage><lpage>64</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="webpage"><source>Randomization</source><comment>Available from: <uri xlink:href="http://www.randomization.com.">http://www.randomization.
com.</uri> (20 Sep 2003)</comment></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>GH</given-names></name><name><surname>Bran</surname><given-names>D</given-names></name><name><surname>McCord</surname><given-names>ML</given-names></name><name><surname>Portera</surname><given-names>JC</given-names></name><name><surname>Ling</surname><given-names>FW</given-names></name></person-group><article-title>Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate</article-title><source>Am J Obstet Gynecol</source><year>1998</year><volume>178</volume><issue>6</issue><fpage>1354</fpage><lpage>1358</lpage><pub-id pub-id-type="pmid">9662322</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraj</surname><given-names>AJ</given-names></name><name><surname>Wilcox</surname><given-names>JG</given-names></name><name><surname>Najmadi</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>MB</given-names></name><name><surname>Paulson</surname><given-names>RJ</given-names></name></person-group><article-title>Resolution of hormonal markers of ectopic gestation: a randomized trial comparing single-dose intramuscular methotrexate with salpingostomy</article-title><source>Obstet Gynecol</source><year>1998</year><volume>92</volume><issue>6</issue><fpage>989</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">9840564</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farquhar</surname><given-names>CM</given-names></name></person-group><article-title>Ectopic pregnancy</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9485</issue><fpage>583</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">16099295</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Mello</surname><given-names>NM</given-names></name><name><surname>Mol</surname><given-names>F</given-names></name><name><surname>Mol</surname><given-names>BW</given-names></name><name><surname>Hajenius</surname><given-names>PJ</given-names></name></person-group><article-title>Conservative management of tubal ectopic pregnancy</article-title><source>Best Pract Res Clin Obstet Gynaecol</source><year>2009</year><volume>23</volume><issue>4</issue><fpage>509</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">19299204</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alleyassin</surname><given-names>A</given-names></name><name><surname>Khademi</surname><given-names>A</given-names></name><name><surname>Aghahosseini</surname><given-names>M</given-names></name><name><surname>Safdarian</surname><given-names>L</given-names></name><name><surname>Badenoosh</surname><given-names>B</given-names></name><name><surname>Hamed</surname><given-names>EA</given-names></name></person-group><article-title>Comparision of success rates in the medical management of ectopic pregnancy with single-dose and multipledose administration of methotrexate: a prospective, randomized clinical trial</article-title><source>Fertil Steril</source><year>2006</year><volume>85</volume><issue>6</issue><fpage>1661</fpage><lpage>1666</lpage><pub-id pub-id-type="pmid">16650421</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soliman</surname><given-names>KB</given-names></name><name><surname>Saleh</surname><given-names>NM</given-names></name><name><surname>Omran</surname><given-names>AA</given-names></name></person-group><article-title>Safety and efficacy of systemic methotrexate in the treatment of unruptured tubal pregnancy</article-title><source>Saudi Med J</source><year>2006</year><volume>27</volume><issue>7</issue><fpage>1005</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">16830020</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivichai</surname><given-names>K</given-names></name><name><surname>Uttavichai</surname><given-names>C</given-names></name><name><surname>Tongsong</surname><given-names>T</given-names></name></person-group><article-title>Medical treatment of ectopic pregnancy: a ten-year review of 106 cases at Maharaj Nakorn Chiang Mai Hospital</article-title><source>J Med Assoc Thai</source><year>2006</year><volume>89</volume><issue>10</issue><fpage>1567</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">17128828</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozenberg</surname><given-names>P</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Camus</surname><given-names>E</given-names></name><name><surname>de Tayrac</surname><given-names>R</given-names></name><name><surname>Garbin</surname><given-names>O</given-names></name><name><surname>de Poncheville</surname><given-names>L</given-names></name><etal/></person-group><article-title>Medical treatment of ectopic pregnancies: a randomized clinical trial comparing methotrexate-mifepristone and methotrexate-placebo</article-title><source>Hum Reprod</source><year>2003</year><volume>18</volume><issue>9</issue><fpage>1802</fpage><lpage>1808</lpage><pub-id pub-id-type="pmid">12923131</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potter</surname><given-names>MB</given-names></name><name><surname>Lepine</surname><given-names>LA</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name></person-group><article-title>Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital</article-title><source>Am J Obstet Gynecol</source><year>2003</year><volume>188</volume><issue>5</issue><fpage>1192</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">12748475</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>GH</given-names></name><name><surname>McCord</surname><given-names>ML</given-names></name><name><surname>Stovall</surname><given-names>TG</given-names></name><name><surname>Huff</surname><given-names>G</given-names></name><name><surname>Portera</surname><given-names>SG</given-names></name><name><surname>Ling</surname><given-names>FW</given-names></name></person-group><article-title>Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>26</issue><fpage>1974</fpage><lpage>1978</lpage><pub-id pub-id-type="pmid">10607814</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowter</surname><given-names>MC</given-names></name><name><surname>Farquhar</surname><given-names>CM</given-names></name></person-group><article-title>Ectopic pregnancy: an update</article-title><source>Curr Opin Obstet Gynecol</source><year>2004</year><volume>16</volume><issue>4</issue><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">15232481</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>GH</given-names></name><name><surname>Stovall</surname><given-names>TG</given-names></name><name><surname>Ling</surname><given-names>FW</given-names></name></person-group><article-title>Nonsurgical treatment of ectopic pregnancy</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>18</issue><fpage>1325</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">11058678</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>A</given-names></name><name><surname>Mashiach</surname><given-names>R</given-names></name><name><surname>Vardy</surname><given-names>M</given-names></name><name><surname>Ovadia</surname><given-names>J</given-names></name></person-group><article-title>Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy</article-title><source>Obstet Gynecol</source><year>1992</year><volume>80</volume><issue>3 Pt 2</issue><fpage>520</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">1495728</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><collab>Isaacs JD Jr, McGehee RP, Cowan BD</collab><article-title>Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: a report of two cases</article-title><source>Obstet Gynecol</source><year>1996</year><volume>88</volume><issue>4 Pt 2</issue><fpage>694</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">8841256</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Job-Spira</surname><given-names>N</given-names></name><name><surname>Fernandez</surname><given-names>H</given-names></name><name><surname>Bouyer</surname><given-names>J</given-names></name><name><surname>Pouly</surname><given-names>JL</given-names></name><name><surname>Germain</surname><given-names>E</given-names></name><name><surname>Coste</surname><given-names>J</given-names></name></person-group><article-title>Ruptured tubal ectopic pregnancy: risk factors and reproductive outcome: results of a population-based study in France</article-title><source>Am J Obstet Gynecol</source><year>1999</year><volume>180</volume><issue>4</issue><fpage>938</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">10203662</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouyer</surname><given-names>J</given-names></name><name><surname>Job-Spira</surname><given-names>N</given-names></name><name><surname>Pouly</surname><given-names>JL</given-names></name><name><surname>Coste</surname><given-names>J</given-names></name><name><surname>Germain</surname><given-names>E</given-names></name><name><surname>Fernandez</surname><given-names>H</given-names></name></person-group><article-title>Fertility following radical, conservative-surgical or medical treatment for tubal pregnancy: a population-based study</article-title><source>BJOG</source><year>2000</year><volume>107</volume><issue>6</issue><fpage>714</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">10847225</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajenius</surname><given-names>PJ</given-names></name><name><surname>Mol</surname><given-names>F</given-names></name><name><surname>Mol</surname><given-names>BW</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Ankum</surname><given-names>WM</given-names></name><name><surname>van der Veen</surname><given-names>F</given-names></name></person-group><article-title>Interventions for tubal ectopic pregnancy</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><issue>1</issue><fpage>CD000324</fpage><lpage>CD000324</lpage><pub-id pub-id-type="pmid">17253448</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouly</surname><given-names>JL</given-names></name><name><surname>Chapron</surname><given-names>C</given-names></name><name><surname>Manhes</surname><given-names>H</given-names></name><name><surname>Canis</surname><given-names>M</given-names></name><name><surname>Wattiez</surname><given-names>A</given-names></name><name><surname>Bruhat</surname><given-names>MA</given-names></name></person-group><article-title>Multifactorial analysis of fertility after conservative laparoscopic treatment of ectopic pregnancy in a series of 223 patients</article-title><source>Fertil Steril</source><year>1991</year><volume>56</volume><issue>3</issue><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">1832649</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipscomb</surname><given-names>GH</given-names></name><name><surname>Givens</surname><given-names>VA</given-names></name><name><surname>Meyer</surname><given-names>NL</given-names></name><name><surname>Bran</surname><given-names>D</given-names></name></person-group><article-title>Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy</article-title><source>Fertil Steril</source><year>2004</year><volume>81</volume><issue>5</issue><fpage>1221</fpage><lpage>1224</lpage><pub-id pub-id-type="pmid">15136080</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>D</given-names></name><name><surname>Panidis</surname><given-names>D</given-names></name><name><surname>Matalliotakis</surname><given-names>I</given-names></name><name><surname>Mavromatidis</surname><given-names>G</given-names></name><name><surname>Neonaki</surname><given-names>M</given-names></name><name><surname>Mamopoulos</surname><given-names>M</given-names></name><etal/></person-group><article-title>Factors that may predispose to rupture of tubal ectopic pregnancy</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2000</year><volume>89</volume><issue>1</issue><fpage>15</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">10733018</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tawfiq</surname><given-names>A</given-names></name><name><surname>Agameya</surname><given-names>AF</given-names></name><name><surname>Claman</surname><given-names>P</given-names></name></person-group><article-title>Predictors of treatment failure for ectopic pregnancy treated with singledose methotrexate</article-title><source>Fertil Steril</source><year>2000</year><volume>74</volume><issue>5</issue><fpage>877</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">11056225</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heard</surname><given-names>K</given-names></name><name><surname>Kendall</surname><given-names>J</given-names></name><name><surname>Abott</surname><given-names>J</given-names></name></person-group><article-title>Rupture of ectopic pregnancy after medical therapy with metothrexate: a case series</article-title><source>J Emerg Med</source><year>1998</year><volume>16</volume><issue>6</issue><fpage>857</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">9848700</pub-id></element-citation></ref></ref-list></back></article>